HHS expects over 1 mln antibody doses from Regeneron, Lilly in 2020

NEW YORK, Oct 9 (Reuters) - A top U.S. health official said on Friday that the government expects to have access to over 1 million doses of Regeneron Pharmaceutical Inc’s and Eli Lilly’s & Co’s antibody treatments for COVID-19 in 2020.

The official, speaking on a call with reporters, said that the government will allocate the treatments to the states based on need, similar to the mechanism they used with Gilead Sciences Inc’s antiviral drug remdesivir for COVID-19.

Both companies have said the drugs were shown to work in clinical trials and that they have submitted an emergency use authorization to the U.S. Food and Drug Administration.

The government official said the U.S. planned to distribute the treatments at no charge to patients, similar to remdesivir. (Reporting by Manas Mishra in Bengalaru and Michael Erman in New York; writing by Caroline Humer; Editing by Chizu Nomiyama)